Day | Untreated control | Lotilaner | Comparison | ||||
---|---|---|---|---|---|---|---|
Mean | Range | Mean | Range | Geometric (arithmetic) mean efficacy (%) | |||
Study 7 | 2 | 26.3 (27.5) | 20–44 | 0.0 (0.0) | 0–0 | 100 (100) | t (6) = 24.7, P < 0.0001 |
9 | 13.8 (15.1) | 4–23 | 0.1 (0.1) | 0–1 | 99.3 (99.2) | t (14) = 13.4, P < 0.000 | |
16 | 18.9 (19.6) | 12–27 | 0.3 (0.5) | 0–3 | 98.4 (97.5) | t (6) = 9.8, P < 0.0001 | |
23 | 27.1 (27.8) | 20–38 | 0.0 (0.0) | 0–0 | 100 (100) | t (6) = 37.0, P < 0.0001 | |
30 | 21.0 (21.3) | 17–28 | 0.1 (0.1) | 0–1 | 99.6 (99.4) | t (14) = 28.6, P < 0.0001 | |
37 | 27.0 (28.0) | 14–38 | 0.2 (0.3) | 0–1 | 99.3 (99.1) | t (6) = 18.5, P < 0.0001 | |
Study 8 | 2 | 18.4 (18.6) | 14–24 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 51.0, P < 0.0001 |
9 | 14.6 (15.0) | 9–21 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 30.4, P < 0.0001 | |
16 | 11.8 (12.8) | 7–21 | 0.0 (0.0) | 0–0 | na | na | |
23 | 13.6 (13.9) | 10–19 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 37.9, P < 0.0001 | |
30 | 10.6 (13.8) | 0–20 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 6.9, P = 0.0002 | |
37 | 14.1 (14.3) | 11–17 | 0.0 (0.0) | 0–0 | 100 (100) | t (7) = 55.1, P < 0.0001 |